Hercules, CA — December 12, 2014 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announced the launch of its new Bio-Plex Pro™ Human Inflammation Panels, multiplex immunoassays that enable detection and quantification of the most comprehensive set of key inflammation biomarkers in a single assay.
Inflammation contributes to seven of the top ten causes of mortality, including heart disease, cancer, and diabetes. This underscores the critical need to identify and monitor underlying inflammation biomarkers — biochemical signs of inflammation — to aid in disease research and drug discovery and development. Other companies have developed products to quantify inflammation biomarkers, but have thus far not been able to deliver a multiplex solution that allows analysis of key inflammation biomarkers in a single assay.
The Bio-Plex Pro Human Inflammation Panel is the first multiplex immunoassay to enable detection of key inflammation biomarkers from the tumor necrosis factor (TNF), human interferon (IFN), matrix metalloproteinases (MMP), and IL-10/regulatory T cell (Treg) cytokine families in one assay. Using this panel, researchers can now study 37 key biomarkers of inflammation simultaneously in a single assay, allowing them to save precious time, money, and sample.
Benefits of Bio-Plex Pro Human Inflammation Panels include:
- Flexible ordering options — the panels are available as premixed and ready-to-use large screening kits (37-plex or 24-plex), a pathway-focused Treg 12-plex kit, singleplex assays, or any custom kits
- Rapid results — multiplex data are generated in 3–4 hours through the use of magnetic beads and protocols that deliver rapid turnaround time
- Easy preparation — Bio-Plex Pro Kits require only a single sample dilution factor and single-level control, simplifying setup
Bio-Plex Pro Human Inflammation Panels are compatible with the Bio-Plex® 100/200,
Bio-Plex® 3D, and Bio-Plex® MAGPIX™ Platforms, as well as all other Luminex-based xMAP Instruments and Software.
For more information about Bio-Rad’s Bio-Plex product portfolio, please visit www.bio‑rad.com/bioplexpr.
About Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The company employs more than 7,800 people worldwide and had revenues exceeding $2.1 billion in 2013. For more information, visit our website at www.bio-rad.com.
This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the “Risk Factors” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.
For more information contact:
Bio-Rad Laboratories, Inc.